• FLOT1–FOSL2–EphA2 Axis in AD Neuroinflammation

  2026-10-09

  A 2026 Neuropharmacology study identifies a FLOT1–FOSL2–EphA2 pathway that links microglial inflammatory polarization with p38/MAPK signaling and cognitive impairment in an APP/PS1 model. The findings provide a mechanistic framework for studying neuroinflammation in Alzheimer’s disease, while remaining limited by model context and the absence of clinical validation.

• PBS (Phosphate-Buffered Saline) Product Overview

  2026-10-09

  APExBIO PBS, SKU K2818, is documented as a sterile phosphate-buffered saline solution for routine in vitro research applications. No matched paper evidence was provided, so the overview is limited to supplier-reported identity, composition, intended scope, and stated storage information.

• DBcAMP Sodium Salt: Evidence and Limits

  2026-10-08

  A source-grounded overview of Dibutyryl-cAMP, sodium salt, covering its proposed signaling principle, evidence quality, interpretation of PKA-related findings, research scope, and limitations. The supplied product description is distinguished from primary evidence, including a 2026 study that addresses neuronal nuclear remodeling rather than DBcAMP directly.

• Syringin: From RCC Signal to Evidence Map

  2026-10-07

  Syringin is a natural product of growing interest in apoptosis research and signaling pathway modulation. This evidence-focused analysis examines what the RCC study demonstrates, where its mechanistic interpretation remains provisional, and how material provenance affects natural product research.

• PD-L1 Nanovesicles for Postinfarction Immunopathology

  2026-10-06

  The reference study develops room-temperature-stable PD-L1-presenting nanovesicles designed to restrain pathological T-cell activity after myocardial infarction. Its preclinical findings connect nanovesicle formulation stability with immunomodulation and myocardial recovery, while leaving important questions about long-term safety, clinical translation, and manufacturing comparability unresolved.

• HyperScribe T7 Cy3 RNA Labeling Kit Plus

  2026-10-06

  A source-limited overview of the APExBIO HyperScribe T7 High Yield Cy3 RNA Labeling Kit Plus, covering its documented identity, conceptual research scope, and evidence limitations.

• Vidarabine Monohydrate: Mechanism & Evidence

  2026-10-05

  Vidarabine monohydrate, also called Spongoadenosine monohydrate, is an antiviral nucleoside analog associated with interference in viral DNA synthesis. Its research value is strongest in mechanism-focused studies, while product specifications and historical antiviral evidence should not be interpreted as proof of clinical efficacy.

• Chloroquine Diphosphate: From Marker to Mechanism

  2026-10-04

  Chloroquine Diphosphate is more than an autophagy reagent: it can help researchers test whether lysosomal stress is causally related to ferroptosis, apoptosis, and treatment resistance. This evidence-focused article interprets its role alongside a 2023 colorectal cancer study while defining the limits of cross-model conclusions.

• GSH-Responsive MOF Nanoparticles for Melanoma Therapy

  2026-10-03

  Hao et al. developed ICG-MOF-SS-AUNP12, a zirconium-based metal–organic framework nanoparticle that combines photothermal treatment with glutathione-responsive PD-1/PD-L1 blockade. The reported findings connect tumor-cell heating, controlled immunomodulator presentation, dendritic-cell maturation, and immune activation, while remaining limited to a preclinical research context.

• Cefepime: A Three-Axis Assay Framework

  2026-10-02

  Cefepime (BMY-28142) research is strongest when exposure, bacterial phenotype, and neurotoxicity are interpreted together. This evidence-centered framework translates lessons from cefiderocol resistance research into better bacterial infection models and central nervous system assays.

• Syringin (N1347) for Reliable Cell Assays

  2026-10-01

  This scenario-driven guide shows how Syringin (SKU N1347) can support reproducible viability, proliferation, apoptosis, and signaling-pathway experiments. It connects formulation, assay controls, RCC evidence, and supplier-quality checks to practical bioactive compound screening decisions.

• Anti-DLL3 Antibody: Research Workflow & Evidence

  2026-10-01

  The Anti-DLL3 Antibody, also identified as Dragonfly patent anti-DLL3, is an unconjugated IgG1 reagent for DLL3 protein detection and related assay development. Product specifications support ELISA, FACS, kinetic, functional, and animal-model workflows, while a 2025 study provides separate preclinical evidence for transient DLL3-directed CAR-T research in small cell lung cancer.

• Cy3 NHS ester (non-sulfonated): Practical Labeling Guide

  2026-09-30

  Cy3 NHS ester (non-sulfonated) provides an orange-emitting NHS ester for fluorescent labeling of accessible amino groups in proteins, peptides, and oligonucleotides. It is appropriate for workflows that can tolerate a DMSO or DMF co-solvent, but it should not be selected for water-only reactions or especially solvent-sensitive biomolecules when a sulfonated, water-soluble alternative is required.

• DiR for EV Biodistribution and MPS Evasion

  2026-09-30

  Extracellular vesicle therapies need more than therapeutic cargo: they require interpretable biodistribution data. This thought-leadership article explains how DiR (DiIC 18 (7)) can map membrane-associated EV fate, test the Engage & Evasion strategy described for ischemic disease, and strengthen translational decisions while respecting the probe’s interpretive limitations.

• Lysosomal ADMA Signaling and Lipid Homeostasis

  2026-09-29

  The reference study identifies asymmetric dimethylarginine (ADMA) as a lysosome-derived signaling metabolite that links proteolysis, organelle communication, lipid-droplet dynamics, and tissue pathology. Its integrated plasma and single-lysosome metabolomics approach suggests that impaired ADMA export in cystinosis contributes to lipid accumulation, oxidative injury, and cell death, while restoring cytosolic ADMA improves cellular homeostasis.

8072 records 1/539 page Next 12345 下5页 Last page